Sana Biotechnology Inc. (SANA)
SANA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.41
-8.02% on the day
Market cap
$721.5M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | SANA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001770121 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-13 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-08-10 |
| Latest current report | 8-K | 2026-09-08 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 389 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.3% |
| 1 month | -26.3% |
| 3 months | -26.5% |
| Year to date | -42.8% |
| 1 year | -46.4% |
| From 52-week high | -60.6% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CADL | Candel Therapeutics Inc. | $9.27 | -5.21% | $709.3M |
| DNA | Ginkgo Bioworks Holdings Inc. | $11.76 | -0.25% | $756.6M |
| FDMT | 4D Molecular Therapeutics Inc. | $12.36 | -4.92% | $682.8M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | +0.89% | $672.0M |
| AURA | Aura Biosciences Inc. | $6.27 | -4.13% | $650.2M |
| ODTX | Odyssey Therapeutics Inc. | $17.24 | -5.59% | $828.5M |
| SLDB | Solid Biosciences Inc. | $5.82 | -13.26% | $624.1M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.89 | -5.99% | $843.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier